|
1) Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan atrial fibrillation stroke trial. Stroke. 2006; 37: 447-51
|
|
|
|
2) ACTIVE Writing Group of the ACTIVE Investi-gators, Connolly S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006; 367: 1903-12
|
|
|
|
|
|
3) Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449-57
|
|
|
|
|
|
4) Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for preventing stroke results from the national registry of atrial fibrillation. JAMA. 2001; 285: 2864-70
|
|
|
|
|
|
5) 心房細動治療(薬物)ガイドライン(2008年改訂版), 循環器病の診断と治療に関するガイドライン(2006年度合同研究班報告). Circ J. 2008; 72(Suppl IV): 1581-638
|
|
|
|
|
6) Yasaka M, Minematsu K, Yamaguchi T, et al. Optimal intensity of international normalized ratio in warfarin therapy for secondary preven-tion of stroke in patients with nonvalvular atrial fibrillation. Intern Med. 2001; 40: 1183-8
|
|
|
|
|
7) Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137: 263-72
|
|
|
|
|
|
8) Lip GY, Frison L, Jonathan L, et al. Identifying patients at high risk for stroke despite antico-agulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010; 41: 2731-8
|
|
|
|
|
|
9) Ohsawa M, Kiyohara Y, Kato I, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol. 2005; 15: 194-6
|
|
|
|
|
|
10) Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009; 137: 102-7
|
|
|
|
|
|
11) The Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison of rate control inpatients with atrial fibrillation. N Engl J Med. 2002; 347: 1825-33
|
|
|
|
|
|
12) Tomita F, et al. Hokkaido Atrial Fibrillation Study Group: Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20, 000 cases in Japan. Jpn Circ J. 2000; 64: 653-8
|
|
|
|
|
|
13) Suzuki S, Yamashita T, Ohtsuka T, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J. 2008; 72: 914-20
|
|
|
|
|
|
14) Kubo M, Kiyohara Y, Kato I, et al. Trends in the Incidence, Mortality, and Survival Rate of Cardiovascular Disease in a Japanese Commu-nity: The Hisayama Study. Stroke. 2003; 34: 2349-54
|
|
|
|
|
|
15) Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke. 2008; 39: 1740-5
|
|
|
|
|
|
16) Hansen ML, Sφrensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170: 1433-41
|
|
|
|
|
|
17) Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010; 138; 1093-100
|
|
|
|
|
|
18) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
19) Eikelboom J, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-72
|
|
|
|
|
|
20) Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study: Stroke. 2010; 41; 1440-4
|
|
|
|
|
|
21) Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119: 987-95
|
|
|
|
|